Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 2/2020

Open Access 01-12-2020 | COVID-19 | Commentary

Biological response modifier glucan through balancing of blood glucose may have a prophylactic potential in COVID-19 patients

Authors: Nobunao Ikewaki, Masaru Iwasaki, Samuel J. K. Abraham

Published in: Journal of Diabetes & Metabolic Disorders | Issue 2/2020

Login to get access

Abstract

With the COVID-19 pandemic causing huge threat to public health and definite treatment modalities and preventive vaccines yet to be arrived at, some of the key indicators of relevance to its prognosis have started emerging. One such independent predictor of outcome has been fasting plasma glucose (FPG) at the time of admission. Earlier, co-morbidities such as diabetes also have been reported to have a risk of relatively increased mortality due to COVID-19. In this background, we herein report on the beneficial effects of Biological response modifier glucan (BRMG) secreted by the black yeast Aureobasidium pullulans AFO-202 which has been proven to bring under control blood sugar levels in human subjects and also has potential in enhancing & regulating the immune parameters in relevance to COVID-19. We further recommend that this BRMG be tried in clinical studies of COVID-19 to provide a prophylactic effect for validation.
Literature
1.
go back to reference Wang S, Ma P, Zhang S, et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia. 2020;63(10):2102-2111. Wang S, Ma P, Zhang S, et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia. 2020;63(10):2102-2111.
3.
go back to reference Novak M, Vetvicka V. Glucans as biological response modifiers. Endocr Metab Immune Disord Drug Targets. 2009;9(1):67–75.CrossRef Novak M, Vetvicka V. Glucans as biological response modifiers. Endocr Metab Immune Disord Drug Targets. 2009;9(1):67–75.CrossRef
4.
go back to reference Sobieralski K, Siwulski M, Lisiecka J, JĊdryczka M, Sas-Golak I, FruĪyĔska-JóĨwiak D. Fungi-Derived β-Glucans as a component of functional food. Acta Sci Pol Hortorum Cultus. 2012;11(4):111–28. Sobieralski K, Siwulski M, Lisiecka J, JĊdryczka M, Sas-Golak I, FruĪyĔska-JóĨwiak D. Fungi-Derived β-Glucans as a component of functional food. Acta Sci Pol Hortorum Cultus. 2012;11(4):111–28.
5.
go back to reference Chen J, Raymond K. Beta-glucans in the treatment of diabetes and associated cardiovascular risks. Vasc Health Risk Manag. 2008;4:1265–72.CrossRef Chen J, Raymond K. Beta-glucans in the treatment of diabetes and associated cardiovascular risks. Vasc Health Risk Manag. 2008;4:1265–72.CrossRef
6.
go back to reference El Khoury D, Cuda C, Luhovyy BL, Anderson GH. Beta glucan: health benefits in obesity and metabolic syndrome. J Nutr Metab. 2012;2012:851362.PubMed El Khoury D, Cuda C, Luhovyy BL, Anderson GH. Beta glucan: health benefits in obesity and metabolic syndrome. J Nutr Metab. 2012;2012:851362.PubMed
7.
go back to reference Cao Y, Zou S, Xu H, et al. Hypoglycemic activity of the Baker’s yeast β-glucan in obese/type 2 diabetic mice and the underlying mechanism. Mol Nutr Food Res. 2016;60:2678–90.CrossRef Cao Y, Zou S, Xu H, et al. Hypoglycemic activity of the Baker’s yeast β-glucan in obese/type 2 diabetic mice and the underlying mechanism. Mol Nutr Food Res. 2016;60:2678–90.CrossRef
8.
go back to reference Francelino Andrade E, Vieira Lobato R, Vasques Araújo T, et al. Effect of beta-glucans in the control of blood glucose levels of diabetic patients: a systematic review. Nutr Hosp. 2014;31:170–7.PubMed Francelino Andrade E, Vieira Lobato R, Vasques Araújo T, et al. Effect of beta-glucans in the control of blood glucose levels of diabetic patients: a systematic review. Nutr Hosp. 2014;31:170–7.PubMed
9.
go back to reference Ikewaki N, Fujii N, Onaka T, Ikewaki S, Inoko H. Immunological actions of Sophy beta-glucan (beta-1,3 – 1,6 glucan), currently available commercially as a health food supplement. Microbiol Immunol. 2007;51:861–73.CrossRef Ikewaki N, Fujii N, Onaka T, Ikewaki S, Inoko H. Immunological actions of Sophy beta-glucan (beta-1,3 – 1,6 glucan), currently available commercially as a health food supplement. Microbiol Immunol. 2007;51:861–73.CrossRef
10.
go back to reference Vetvicka V, Vetvickova J. Comparison of immunological effects of commercially available beta-glucans: part III. Int Clin Pathol J. 2016;2:78–83. Vetvicka V, Vetvickova J. Comparison of immunological effects of commercially available beta-glucans: part III. Int Clin Pathol J. 2016;2:78–83.
11.
go back to reference Li X, Wang J, Wang W, Liu C, Sun S, Gu J, Wang X, Boraschi D, Huang Y, Qu D. Immunomodulatory activity of a novel, synthetic beta-glucan (β-glu6) in murine macrophages and human peripheral blood mononuclear cells. PLoS One. 2013;8:e80399.CrossRef Li X, Wang J, Wang W, Liu C, Sun S, Gu J, Wang X, Boraschi D, Huang Y, Qu D. Immunomodulatory activity of a novel, synthetic beta-glucan (β-glu6) in murine macrophages and human peripheral blood mononuclear cells. PLoS One. 2013;8:e80399.CrossRef
12.
go back to reference Yano et al. Sophy Beta-Glucan is effective in alleviating increased blood sugar levels. Abstract presented at the 55th Conference of the Japanese Society of Nutrition and Dietetics 2008. Yano et al. Sophy Beta-Glucan is effective in alleviating increased blood sugar levels. Abstract presented at the 55th Conference of the Japanese Society of Nutrition and Dietetics 2008.
13.
go back to reference Dedeepiya VD, Sivaraman G, Venkatesh AP, et al. Potential effects of nichi glucan as a food supplement for diabetes mellitus and hyperlipidemia: preliminary findings from the study on three patients from India. Case Rep Med. 2012;2012:895370.CrossRef Dedeepiya VD, Sivaraman G, Venkatesh AP, et al. Potential effects of nichi glucan as a food supplement for diabetes mellitus and hyperlipidemia: preliminary findings from the study on three patients from India. Case Rep Med. 2012;2012:895370.CrossRef
15.
go back to reference Kolluru GK, Bir SC, Kevil CG. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med. 2012;2012:918267.PubMedPubMedCentral Kolluru GK, Bir SC, Kevil CG. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med. 2012;2012:918267.PubMedPubMedCentral
16.
go back to reference Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol. 1999;26:259–65.CrossRef Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol. 1999;26:259–65.CrossRef
17.
go back to reference Rao KS, Suryaprakash V, Senthilkumar R, et al. Role of Immune Dysregulation in Increased Mortality Among a Specific Subset of COVID-19 Patients and Immune-Enhancement Strategies for Combatting Through Nutritional Supplements. Front Immunol. 2020;11:154.CrossRef Rao KS, Suryaprakash V, Senthilkumar R, et al. Role of Immune Dysregulation in Increased Mortality Among a Specific Subset of COVID-19 Patients and Immune-Enhancement Strategies for Combatting Through Nutritional Supplements. Front Immunol. 2020;11:154.CrossRef
18.
go back to reference Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med. 1996;28:419–26.CrossRef Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med. 1996;28:419–26.CrossRef
19.
go back to reference Murphy EJ, Masterson C, Rezoagli E, et al. β-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects - Implications for coronavirus disease (COVID-19) immunotherapies. Sci Total Environ. 2020;732:139330.CrossRef Murphy EJ, Masterson C, Rezoagli E, et al. β-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects - Implications for coronavirus disease (COVID-19) immunotherapies. Sci Total Environ. 2020;732:139330.CrossRef
20.
go back to reference Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne). 2013;4:37.CrossRef Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne). 2013;4:37.CrossRef
21.
go back to reference Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. 2014;18:1–14.CrossRef Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. 2014;18:1–14.CrossRef
22.
go back to reference Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract. 2020;162:108142. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract. 2020;162:108142.
24.
go back to reference de Lucena TMC, da Silva Santos AF, de Lima BR, de Albuquerque Borborema ME, de Azevêdo Silva J. Mechanism of inflammatory response in associated comorbidities in COVID-19. Diabetes Metab Syndr. 2020;14:597–600.CrossRef de Lucena TMC, da Silva Santos AF, de Lima BR, de Albuquerque Borborema ME, de Azevêdo Silva J. Mechanism of inflammatory response in associated comorbidities in COVID-19. Diabetes Metab Syndr. 2020;14:597–600.CrossRef
25.
go back to reference Petit J, Bailey EC, Wheeler RT, de Oliveira CAF, Forlenza M, Wiegertjes GF. Studies Into β-Glucan Recognition in Fish Suggests a Key Role for the C-Type Lectin Pathway. Front Immunol. 2019;10:280.CrossRef Petit J, Bailey EC, Wheeler RT, de Oliveira CAF, Forlenza M, Wiegertjes GF. Studies Into β-Glucan Recognition in Fish Suggests a Key Role for the C-Type Lectin Pathway. Front Immunol. 2019;10:280.CrossRef
26.
go back to reference Adachi Y, Ishii T, Ikeda Y, Hoshino A, Tamura H, Aketagawa J, Tanaka S, Ohno N. Characterization of beta-glucan recognition site on C-type lectin, dectin 1. Infect Immun. 2004;72:4159–71.CrossRef Adachi Y, Ishii T, Ikeda Y, Hoshino A, Tamura H, Aketagawa J, Tanaka S, Ohno N. Characterization of beta-glucan recognition site on C-type lectin, dectin 1. Infect Immun. 2004;72:4159–71.CrossRef
Metadata
Title
Biological response modifier glucan through balancing of blood glucose may have a prophylactic potential in COVID-19 patients
Authors
Nobunao Ikewaki
Masaru Iwasaki
Samuel J. K. Abraham
Publication date
01-12-2020
Publisher
Springer International Publishing
Keyword
COVID-19
Published in
Journal of Diabetes & Metabolic Disorders / Issue 2/2020
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-020-00664-4

Other articles of this Issue 2/2020

Journal of Diabetes & Metabolic Disorders 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine